Kellitai (300326.SZ) released its 2023 annual report. The company's revenue was 956 million yuan,...
According to the Zhitong Finance App, Kelly Thai (300326.SZ) released its 2023 annual report. The company's revenue was 956 million yuan, a decrease of 17.99% over the previous year. Net profit attributable to shareholders of listed companies was $113 million. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was RMB 61.648,800. Basic earnings per share were $0.157. In addition, it is proposed to distribute a cash dividend of 0.6 yuan (tax included) for every 10 shares to all shareholders.
According to the announcement, the company's overall business performance changed significantly compared to the same period last year. The main reason was that the national high-value spinal consumables procurement policy was gradually implemented in various regions during the reporting period. The company's major orthopedic businesses, such as vertebral body plastic surgery, minimally invasive spine, radiofrequency ablation, and trauma products, were affected by volume procurement policies, and the sales prices of various products within the scope of collection dropped sharply. As a result, the company's operating income and gross margin declined year-on-year, which had a significant adverse impact on the company's main business performance.